CLINICAL TRIALS PROFILE FOR PATADAY
✉ Email this page to a colleague
All Clinical Trials for Pataday
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00534794 ↗ | Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2007-10-01 | The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis. |
| NCT01272089 ↗ | A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis | Completed | Alcon Research | Phase 4 | 2011-05-01 | The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study. |
| NCT01450176 ↗ | Comparing Patient Satisfaction With Pataday or Bepreve | Completed | McCabe Vision Center | N/A | 2011-09-01 | The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID). |
| NCT01470118 ↗ | A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis | Completed | Allergan | Phase 4 | 2011-10-01 | This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis. |
| NCT01732757 ↗ | A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis | Completed | Allergan | Phase 4 | 2012-11-01 | This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis. |
| NCT05265910 ↗ | A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis | Recruiting | Andover Research Eye Institute | Phase 4 | 2021-12-14 | This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Pataday
Condition Name
Clinical Trial Locations for Pataday
Trials by Country
Clinical Trial Progress for Pataday
Clinical Trial Phase
Clinical Trial Sponsors for Pataday
Sponsor Name
